Skip to main content

Advertisement

SpringerLink
Log in

A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema

  • Original paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose To evaluate the effect of intravitreal triamcinolone acetonide (IVT) on refractory diabetic macular edema (DME). Methods In a prospective, placebo-controlled, randomized clinical trial, 88 eyes of 61 patients with clinically significant macular edema that would have responded unfavourably to laser photocoagulation were randomly assigned to two groups. The treatment group (45 eyes) received 4 mg IVT and the control group (43 eyes) received a placebo subconjunctival injection. The primary outcome was central macular thickness (CMT) measured by optical coherence tomography. Complete examination was repeated at 2 and 4 months post-intervention. Results The mean (SD) CMT before the intervention and at the 2- and 4-month follow-ups was 393 (151), 293 (109) and 362 (119) μm in the treatment group and 393 (166), 404 (134) and 405 (160) μm in the placebo group, respectively. The second month difference was significant (P = 0.01). The difference between visual acuity changes (0.15 logarithm of the minimum angle of resolution, logMAR) was significant at 2 months (P = 0.02) but reduced to 0.11 logMAR (P = 0.08) after 4 months. Reduction for hard exudates and petaloid pattern were significantly greater in cases at 4 months. Conclusions The therapeutic effect of IVT on DME is greatest at 2 months and decreases up to the fourth month post-intervention. However, in terms of cystoid macular edema and hard exudates, the effect is maintained up to 4 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

BUN:

Blood urea nitrogen

CME:

Cystoid macular edema

CMT:

Central macular thickness

CSME:

Clinically significant macular edema

DME:

Diabetic macular edema

ETDRS:

Early treatment diabetic retinopathy study

FBS:

Fasting blood sugar

HE:

Hard exudates

IOP:

Intraocular pressure

LogMAR:

Logarithm of the minimum angle of resolution

MPC:

Macular photocoagulation

NVI:

Neovascularization of iris

OCT:

Optical coherence tomography

PRP:

Panretinal photocoagulation

VA:

Visual acuity

References

  1. Ferris FL III, Patz A (1984) Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 28[Suppl]:S452–S461

    Article  Google Scholar 

  2. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796–1806

    Google Scholar 

  3. Early Treatment Diabetic Retinopathy Study Research Group (1987) Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: early treatment diabetic retinopathy study report number 2. Ophthalmology 94:761–774

    Google Scholar 

  4. Olk RJ (1989) Diabetic retinopathy. In: Yannuzzi LA (ed) Laser photocoagulation of the macula. JB Lippincott, Philadelphia

    Google Scholar 

  5. McMeel JW, Trempe CL, Franks EB (1977) Diabetic maculopathy. Trans Am Acad Ophthalmol Otolaryngol 83:476–487

    Google Scholar 

  6. Early Treatment Diabetic Retinopathy Study Research Group (1995) Focal photocoagulation treatment of diabetic macular edema. Relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report No. 19. Arch Ophthalmol 113:1144–1155

    Google Scholar 

  7. Cantrill HL (1984) The diabetic retinopathy study and the early treatment diabetic retinopathy study. Int Ophthalmol Clin 24:13–29

    Article  PubMed  CAS  Google Scholar 

  8. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW, Penn State Retina Research Group (2002) Diabetic retinopathy: more than meets the eye. Surv Ophthalmol 47(suppl 2):S253–S256

    Article  PubMed  Google Scholar 

  9. Bakri SJ, Kaiser PK (2005) Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 139:290–294

    Article  PubMed  CAS  Google Scholar 

  10. Jonas JB, Sofker A (2001) Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 132:425–427

    Article  PubMed  CAS  Google Scholar 

  11. Martidis A, Duker JS, Greenberg PB et al. (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920–926

    Article  PubMed  Google Scholar 

  12. Jonas JB, Kreissig I, Sofker A, Degenring RF (2003) Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 121:57–61

    Article  PubMed  CAS  Google Scholar 

  13. Tan DT, Chee SP, Lim L, Lim AS (1999) Randomized clinical trial of a new dexamethasone delivery system (Surodex) for treatment of post-cataract surgery inflammation. Ophthalmology 106:223–231

    Article  PubMed  CAS  Google Scholar 

  14. Beer PM, Bakri SJ (2003) Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 110:681–686

    Article  PubMed  Google Scholar 

  15. Nelson ML, Tentant MTS (2003) Infectious and presumed noninfectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 23:686–691

    Article  PubMed  Google Scholar 

  16. Rodriguez-Coleman H, Yuan P, Kim H, Gravlin L, Srivastava S, Csaky KG, Robinson MR (2004) Intravitreal injection of triamcinlone for diffuse macular edema. Arch Ophthalmol 122:1085–1086

    Google Scholar 

  17. Jonas JB, Kreissig I, Degenring R (2003) Intraocular pressure after injection of triamcinolone acetonide. Br J Ophthalmol 87:24–27

    Article  PubMed  CAS  Google Scholar 

  18. Danis RP, Ciulla TA, Pratt LM, Anliker W (2000) Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 20:244–250

    Article  PubMed  CAS  Google Scholar 

  19. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S (2004) Intravitreal triamcinolone for the treatment of refractory diabetic macular oedema with hard exudates: an optical coherence tomography study. Br J Ophthalmol 88:1131–1136

    Google Scholar 

  20. Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044–2049

    Article  PubMed  Google Scholar 

  21. Massin P, Audren F, Haouchine B et al (2004) Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111:218–224

    Article  PubMed  Google Scholar 

  22. Goebel W, Kretzchmar-Gross T (2002) Retinal thickness in diabetic retinopathy. Retina 22:759–767

    Article  PubMed  Google Scholar 

  23. Otani T, Kishi S (2001) Tomographic findings of foveal hard exudates in diabetic macular edema. Am J Ophthalmol 131:50–54

    Article  PubMed  CAS  Google Scholar 

  24. Nussenblatt RB, Kaufman SC, Palestin AG (1987) Macular thickening and visual acuity. Measurements in patients with cystoid macular edema. Ophthalmology 94:1134–1139

    PubMed  CAS  Google Scholar 

  25. Yasukawa I, Kiryu J, Tsujikawa A, Dong J, Suzuma I, Takagi H, Ogura Y (1998) Quantitative analysis of foveal retinal thickness in diabetic retinopathy with the scanning retinal thickness analyzer. Retina 18:150–155

    Google Scholar 

  26. Shahidi M, Ogura Y, Blair NP (1991) Retinal thickness analysis for quantitative assessment of diabetic macular edema. Arch Ophthalmol 109:1115–1120

    PubMed  CAS  Google Scholar 

  27. Jonas JB, Kreissig I, Degenring RF (2003) Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol 136:384–386

    Article  PubMed  CAS  Google Scholar 

  28. Conway MD, Canakis C, Livir-Rallatos C, Peyman GA (2003) Intravitreal triamcinolone acetonide for refractory chronic pseudophakic cystoid macular edema. J Cataract Refract Surg 291:27–33

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by the Ophthalmic Research Centre of Shaheed Beheshti Medical University.

Author information

Authors and Affiliations

  1. Ophthalmic Research Centre of Shaheed Beheshti Medical University, Labbafinejad Medical Centre, Pasdaran Ave. Boostan 9 St., Tehran, 16666, Iran

    Mohammad H. Dehghan, Hamid Ahmadieh, Alireza Ramezani, Morteza Entezari & Arash Anisian

Authors
  1. Mohammad H. Dehghan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Ahmadieh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alireza Ramezani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Morteza Entezari
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arash Anisian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hamid Ahmadieh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dehghan, M.H., Ahmadieh, H., Ramezani, A. et al. A randomized, placebo-controlled clinical trial of intravitreal triamcinolone for refractory diabetic macular edema. Int Ophthalmol 28, 7–17 (2008). https://doi.org/10.1007/s10792-007-9097-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-007-9097-y

Keywords

Search

Navigation